Eszopiclone Classification
Eszopiclone is a Schedule IV controlled substance under the Controlled Substances Act. 1
Regulatory Classification
Eszopiclone is explicitly classified as a Schedule IV controlled substance by the Drug Enforcement Administration (DEA), placing it in the same category as other benzodiazepine receptor agonists (BzRAs) including zolpidem and zaleplon 2, 1. This classification reflects its potential for abuse and dependence, though lower than Schedule II or III substances.
Clinical Context
The Schedule IV designation means eszopiclone:
- Requires DEA registration for prescribing and dispensing
- Has prescription limitations under federal and state regulations
- Carries abuse potential that necessitates careful patient selection and monitoring 1
Multiple clinical guidelines consistently identify eszopiclone as part of the benzodiazepine receptor agonist class of Schedule IV controlled substances when discussing pharmacologic treatment options for insomnia 2. This classification applies to all formulations and dosages (1 mg, 2 mg, and 3 mg tablets).
Important Prescribing Considerations
Given its Schedule IV status, prescribers should:
- Exercise particular caution in patients with a history of substance abuse or dependence 1
- Consider non-scheduled alternatives (such as ramelteon, a melatonin receptor agonist) for patients with substance use disorder history 2
- Monitor for signs of misuse, including dose escalation or drug-seeking behavior
- Store and dispense according to DEA regulations for controlled substances
The controlled substance classification reflects documented abuse liability studies showing that eszopiclone at doses of 6-12 mg produced euphoric effects similar to diazepam 20 mg in individuals with known histories of benzodiazepine abuse 1.